{"id":389314,"date":"2022-12-27T00:00:00","date_gmt":"2022-12-27T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfon0009-2022-biopharma-myelofibrosis-niche-rare-disease-landscape-forecast-us-eu5-2022\/"},"modified":"2026-04-17T11:26:39","modified_gmt":"2026-04-17T11:26:39","slug":"nrlfon0009-2022-biopharma-myelofibrosis-niche-rare-disease-landscape-forecast-us-eu5-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfon0009-2022-biopharma-myelofibrosis-niche-rare-disease-landscape-forecast-us-eu5-2022\/","title":{"rendered":"Myelofibrosis | Niche &#038; Rare Disease Landscape &#038; Forecast | US\/EU5 | 2022"},"content":{"rendered":"<p>Myelofibrosis (MF) is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Symptoms include severe anemia, weakness, fatigue, and splenomegaly. The\u00a0JAK\u00a0inhibitors ruxolitinib, fedratinib, and pacritinib are the only drugs approved for\u00a0MF\u00a0in the United States and\u00a0EU5\u00a0(pacritinib in the United States only). Although\u00a0JAK\u00a0inhibitors offer a therapeutic option, they are associated with high discontinuation rates and are unable to address all\u00a0MF\u00a0symptoms. Therefore, significant market opportunity remains for safe and tolerable treatments that can effectively manage the full spectrum of\u00a0MF\u00a0symptoms (thus reducing the need for polypharmacy) and that can treat patients with thrombocytopenia and anemia.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the sizes of the U.S. and\u00a0EU5\u00a0diagnosed prevalent and incident primary and secondary\u00a0MF\u00a0populations? What are the distributions of risk level among diagnosed incident and prevalent cases of primary\u00a0MF?<\/li>\n<li>What is the current treatment landscape for\u00a0MF? What are physicians\u2019 experience and satisfaction with current therapies?<\/li>\n<li>How have ruxolitinib, fedratinib, and pacritinib been integrated into the\u00a0MF\u00a0treatment algorithm? How will these drugs compete in the treatment of\u00a0MF?<\/li>\n<li>What are the key unmet needs and areas of commercial opportunity for\u00a0MF? How will novel therapies impact the treatment algorithm for\u00a0MF, and which\u00a0MF\u00a0patients will be served by these treatment options in 2031?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>Niche &#038; Rare Disease Landscape &#038; Forecast<\/em>\u00a0provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>SOLUTION ENHANCEMENT<\/strong><\/p>\n<p><em>Niche &#038; Rare Disease Landscape &#038; Forecast<\/em>\u00a0introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389314","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-myelofibrosis","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389314","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389314\/revisions"}],"predecessor-version":[{"id":576146,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389314\/revisions\/576146"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389314"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}